Flexion Therapeutics, Inc.
FLXN
FLXN was delisted on the 18th of November, 2021.
145 hedge funds and large institutions have $230M invested in Flexion Therapeutics, Inc. in 2021 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 51 increasing their positions, 34 reducing their positions, and 23 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 34
30% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 23
4% more funds holding
Funds holding: 140 → 145 (+5)
2% less call options, than puts
Call options by funds: $2.22M | Put options by funds: $2.27M
38% less capital invested
Capital invested by funds: $372M → $230M (-$141M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$13M |
| 2 |
PCMI
Paradigm Capital Management Inc
Albany,
New York
|
+$3.92M |
| 3 |
FAM
Fred Alger Management
New York
|
+$2.73M |
| 4 |
EIP
Easterly Investment Partners
Beverly,
Massachusetts
|
+$1.96M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$26.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$17.6M |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$7.35M |
| 4 |
Goldman Sachs
New York
|
-$6.29M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$5.79M |
FLXN Hedge Fund Activity: Q3 2021 in Review
145 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Flexion Therapeutics, Inc. (FLXN) for Q3 2021, worth a combined $230M — down 38% from $372M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new FLXN positions and 23 closed out — a net gain of 7 holders — while 51 added to existing stakes and 34 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $13M. The largest seller was Artisan Partners, exiting entirely with an estimated $26.8M sold.
- 145 institutional investors held Flexion Therapeutics, Inc. (FLXN) as of Q3 2021, up from 140 in Q2 2021.
- Funds reported $230M of Flexion Therapeutics, Inc. stock for Q3 2021, down 38% quarter-over-quarter.
- 30 funds opened new Flexion Therapeutics, Inc. positions in Q3 2021 and 23 closed out, a net change of +7 holders.
- The largest Flexion Therapeutics, Inc. buyer in Q3 2021 was Soleus Capital Management, an estimated $13M added.
- The largest Flexion Therapeutics, Inc. seller in Q3 2021 was Artisan Partners, an estimated $26.8M sold.
Based on aggregated 13F filings for Q3 2021.